Scholarlink

Background <p>The pilot implementation of the RTSS/AS01<sub>E</sub> (RTS,S) malaria vaccine in Ghana, Kenya, and Malawi marked a significant step in the fight against malaria. Given the scale of the rollout, which far exceeded the controlled environment of clinical trials, establishing a robust pharmacovigilance (PV) system to monitor rare but potentially serious adverse events following immunization (AEFIs) was a critical component of the program’s design.</p> Methods and results <p>In collaboration with technical partners, national health authorities monitored the safety of the RTS,S/AS01<sub>E</sub> vaccine through strengthened existing routine pharmacovigilance systems and strategies in the three participating countries. Causality assessment of serious AEFIs by national expert advisory committees did not reveal any new safety concerns associated with the RTS,S/AS01<sub>E</sub> vaccine or confirm the safety signals observed in the Phase 3 clinical trials. The PV efforts successfully supported the safe rollout of the vaccine, contributing to substantial public health benefits in these endemic regions. Challenges encountered included underreporting of AEFIs, delays in data submission and in investigating serious AEFIs, and poor report quality despite targeted investments to strengthen the systems.</p> Conclusions and recommendations <p>The pilot program highlighted PV challenges in resource-limited settings and provided useful insights for future vaccine rollouts. The lessons learned from these challenges emphasize the importance of sustained investment, particularly for AEFI investigations, and the need for innovations to improve health worker reporting. Research is needed to identify effective strategies for increasing reporting. Key recommendations include training and capacity building, resource allocation, surveillance and reporting, raising and maintaining public awareness, and collaboration and information sharing to ensure sustained PV efforts and robust safety surveillance in similar contexts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety monitoring of the RTS,S/AS01E malaria vaccine: experiences and lessons from routine pharmacovigilance in Ghana, Kenya, and Malawi

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月4日

查看全文
  • Adela Ashie,
  • Martha Mandale,
  • Anderson Ndalama,
  • Delese Darko,
  • Seth Seaneke,
  • Eric K. Boateng,
  • George Sabblah,
  • Abena Asamoa-Amoakohene,
  • Kwame Amponsa-Achiano,
  • Naziru T. Mohammed,
  • Rose Jalang’o,
  • Edwin Nkansah,
  • Yvonne Adu-Boahen,
  • Fred Siyoi,
  • Anthony Toroitich,
  • Christabel Khaemba,
  • Pamela Nambwa,
  • Sujeet Jain,
  • Rafiq N. A. Okine,
  • Alambo K. Mssusa

摘要

Background

The pilot implementation of the RTSS/AS01E (RTS,S) malaria vaccine in Ghana, Kenya, and Malawi marked a significant step in the fight against malaria. Given the scale of the rollout, which far exceeded the controlled environment of clinical trials, establishing a robust pharmacovigilance (PV) system to monitor rare but potentially serious adverse events following immunization (AEFIs) was a critical component of the program’s design.

Methods and results

In collaboration with technical partners, national health authorities monitored the safety of the RTS,S/AS01E vaccine through strengthened existing routine pharmacovigilance systems and strategies in the three participating countries. Causality assessment of serious AEFIs by national expert advisory committees did not reveal any new safety concerns associated with the RTS,S/AS01E vaccine or confirm the safety signals observed in the Phase 3 clinical trials. The PV efforts successfully supported the safe rollout of the vaccine, contributing to substantial public health benefits in these endemic regions. Challenges encountered included underreporting of AEFIs, delays in data submission and in investigating serious AEFIs, and poor report quality despite targeted investments to strengthen the systems.

Conclusions and recommendations

The pilot program highlighted PV challenges in resource-limited settings and provided useful insights for future vaccine rollouts. The lessons learned from these challenges emphasize the importance of sustained investment, particularly for AEFI investigations, and the need for innovations to improve health worker reporting. Research is needed to identify effective strategies for increasing reporting. Key recommendations include training and capacity building, resource allocation, surveillance and reporting, raising and maintaining public awareness, and collaboration and information sharing to ensure sustained PV efforts and robust safety surveillance in similar contexts.